Remikiren
From Self-sufficiency
| File:Remikiren.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
(2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-4-yl)propanamide | |
| Pharmacokinetic data | |
| Protein binding | 83% |
| Identifiers | |
| CAS Number | 126222-34-2 |
| ATC code | C09XA01 (WHO) |
| PubChem | CID 5462340 |
| DrugBank | APRD00163 |
| Chemical data | |
| Formula | C33H50N4O6S |
| Molar mass | 630.839 g/mol[[Script error: No such module "String".]] |
Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]
References
- ↑ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica. 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Renin inhibitors
- Cardiovascular system drug stubs
- 2Fix
